William Blair Analysts Raise Earnings Estimates for Enovis

Enovis Co. (NYSE:ENOV) – Analysts at William Blair increased their Q1 2025 earnings per share estimates for Enovis in a report issued on Wednesday, February 26th. William Blair analyst B. Vazquez now forecasts that the company will post earnings of $0.75 per share for the quarter, up from their previous estimate of $0.70. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis’ Q2 2025 earnings at $0.70 EPS, Q3 2025 earnings at $0.76 EPS, FY2025 earnings at $3.16 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $1.05 EPS and FY2026 earnings at $3.48 EPS.

Separately, Needham & Company LLC cut their price objective on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday.

Enovis Stock Performance

Shares of ENOV opened at $38.16 on Friday. Enovis has a 12-month low of $38.08 and a 12-month high of $63.96. The stock has a market cap of $2.17 billion, a P/E ratio of -17.42 and a beta of 1.94. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $44.90 and a two-hundred day moving average of $44.34.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENOV. Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the 4th quarter worth about $29,000. Quadrant Capital Group LLC lifted its stake in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after buying an additional 239 shares during the period. UMB Bank n.a. boosted its position in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the last quarter. Finally, Quarry LP raised its holdings in Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 749 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.